Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PUR3100 in Healthy Adults
NCT05351086Phase 1Completed
- Sponsor
- Pulmatrix, Inc.
- Start
- Jun 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dihydroergotamine in migraine (4 arms), sponsored by Pulmatrix, Inc. Primary endpoints: Safety and Tolerability, Maximum Plasma Concentration and 7 more. Started Jun 2022; status: completed.
02
Drugs
dihydroergotamine
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05351086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05351086.